| Literature DB >> 29185148 |
Rajendra Awasthi1, Michael John Rathbone2,3, Philip Michael Hansbro4, Mary Bebawy5, Kamal Dua6,7.
Abstract
MicroRNAs (miRNAs) represent a new class of diagnostic and prognostic biomarker as well as new therapeutic targets in cancer therapy. miRNAs are gaining significant interest due to extensive advancements in knowledge since their discovery and, more recently, their translational application as therapeutic moieties and targets in the management of disease. miRNAs used in the treatment of cancer would position them as a new class of emerging therapeutic agents. Indeed, numerous candidate miRNAs have been identified as having therapeutic application in the treatment of cancer, but there is still much to learn about how to transform these into effective, patient-compliant, and targeted drug delivery systems. In this mini review, we discuss the utility and potential of nanotechnology in miRNA formulation and delivery with particular emphasis on cancer, including their role in conferring multidrug resistance and metastatic capacity. This review benefits both the formulation and biological scientists in understanding and exploring the new vistas of miRNA delivery using nanotechnology in the cancer clinically.Entities:
Keywords: Cancer; Extracellular vesicles; Metastasis; MicroRNA; Microparticles; Multidrug resistance; Nanotechnology; P-Glycoprotein
Mesh:
Substances:
Year: 2018 PMID: 29185148 DOI: 10.1007/s13346-017-0440-1
Source DB: PubMed Journal: Drug Deliv Transl Res ISSN: 2190-393X Impact factor: 4.617